Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Vaginal gel may provide a new approach to HIV prevention

01.11.2005


Research with female monkeys at the Tulane National Primate Research Center has for the first time shown that three different anti-viral agents in a vaginal gel protect the animals against an HIV-like virus. The research suggests that a microbicide using compounds that inhibit the processes by which HIV attaches to and enters target cells could potentially provide a safe, effective and practical way to prevent HIV transmission in women, according to study investigators. The study, published online October 30 in the journal Nature was funded principally by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.



Additionally, in a first-of-its-kind joint announcement, two of the world’s leading pharmaceutical companies, Merck & Co. and Bristol-Myers Squibb (BMS) today announced that they have signed separate license agreements with the International Partnership for Microbicides to develop two of the compounds evaluated in the study as potential vaginal microbicides to protect women from HIV. Under the agreements, Merck and BMS each will grant the non-profit group a royalty-free license to develop, manufacture and distribute their compounds for use as microbicides in resource-poor countries. Announced on the eve of the TIME Global Health Summit, this agreement marks the first time any pharmaceutical company has licensed an anti-HIV compound for development as a microbicide when the class of drugs is so early in development.

Women make up nearly half of all people living with HIV worldwide, and 80 percent of new cases of HIV infection in women result from heterosexual intercourse. A vaginal gel containing microbicides could be applied topically to reduce the transmission of HIV and other sexually transmitted infections.


Ronald Veazey, chair of the Division of Comparative Pathology at the Tulane National Primate Research Center, lead author of the paper, conducted the research with simian-human immunodeficiency virus (SHIV), a hybrid virus made in the laboratory from HIV and its cousin, SIV, which infects only monkeys.

The Tulane team tested gels containing two small molecules and a peptide -- alone and in combination --designed to block SHIV from fusing with its target cells at or near the tissue lining of the vagina, to see whether this would prevent the virus from entering the monkeys’ bodies. The test compounds were provided by Bristol-Myers Squibb Inc., Merck Research Laboratories and Weill Medical College of Cornell University.

To test the microbicides, the Tulane team first gave the monkeys a long-acting hormonal form of birth control (Depo-Provera) to synchronize their menstrual cycles and thin the vaginal membrane, which increases susceptibility to virus infection, Veazey says. During testing, researchers placed the experimental gels in the animals’ vaginas. Thirty minutes later, the animals were exposed to high-dose SHIV.

The three inhibitors were each effective when used alone and also when tested in combination. Of 20 monkeys given the BMS and Merck microbicides in combination, 16 were protected from infection. All three monkeys given the triple combination of microbicides remained virus-free. None of the monkeys experienced vaginal irritation or inflammation from the experimental gels.

"We felt these inhibitors were likely to be pretty safe. Compounds similar to them have a good safety record in humans, at least so far," Veazey says.

"This study demonstrates that combination microbicides are feasible," says NIAID Director Anthony Fauci. "We need to build on these promising animal studies and move toward establishing the safety and effectiveness of combination microbicides in women."

Fran Simon | EurekAlert!
Further information:
http://www.tulane.edu

More articles from Health and Medicine:

nachricht Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>